The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XVII.g

Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo

In patients exposed to TNF-alpha antagonists, tuberculosis can be pulmonary or extrapulmonary. The expression of pulmonary TB in such patients may differ from that in person unexposed to such drugs (PMID: 24365560). A search for LTBI prior to comencement of treatment is indicated using IGRA test (PMID 20810871)

Publications

Wang X, Wong SH, Wang XS, Tang W, Liu CQ, Niamul G, Wu B, Tam LS, Wu JCY, Chan FKL, Sung JJY, Ng SC

Risk of tuberculosis in patients with immune-mediated diseases on biological therapies: a population-based study in a tuberculosis endemic region.

Rheumatology (Oxford, England). 2019;58(5):803-810

Kang J, Jeong DH, Han M, Yang SK, Byeon JS, Ye BD, Park SH, Hwang SW, Shim TS, Jo KW

Incidence of Active Tuberculosis within One Year after Tumor Necrosis Factor Inhibitor Treatment according to Latent Tuberculosis Infection Status in Patients with Inflammatory Bowel Disease.

Journal of Korean medical science. 2018;33(47):e292

Rutherford AI, Patarata E, Subesinghe S, Hyrich KL, Galloway JB

Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.

Rheumatology (Oxford, England). 2018;57(6):997-1001

Chan MJ, Wen YH, Huang YB, Chuang HY, Tain YL, Lily Wang YC, Hsu CN

Risk of tuberculosis comparison in new users of antitumour necrosis factor-α and with existing disease-modifying antirheumatic drug therapy.

Journal of clinical pharmacy and therapeutics. 2018;43(2):256-264

Lee JW, Choi CH, Park JH, Kim JW, Kang SB, Koo JS, Kim YH, Kim YS, Joo YE, Chang SK

Clinical features of active tuberculosis that developed during anti-tumor necrosis factor therapy in patients with inflammatory bowel disease.

Intestinal research. 2016;14(2):146-51

Chang CH, Ruan SY, Huang CT

Disseminated tuberculosis in a patient treated with biologics.

American journal of respiratory and critical care medicine. 2015;191(5):592-3

Ishiguro T, Takayanagi N, Kagiyama N, Yanagisawa T, Sugita Y

Characteristics of tuberculosis in patients with rheumatoid arthritis: a retrospective single-center study.

Internal medicine (Tokyo, Japan). 2014;53(12):1291-8

Huang LK, Wu MH, Chang SC

Radiological manifestations of pulmonary tuberculosis in patients subjected to anti-TNF-α treatment.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 2014;18(1):95-101

Cappell MS, Saad A, Bortman JS, Amin M

Ileocolonic tuberculosis clinically, endoscopically, and radiologically mimicking Crohn's disease: disseminated infection after treatment with infliximab.

Journal of Crohn's & colitis. 2014;8(6):560-2

Ribeiro C, Correia AM, Duarte R

Tuberculosis and TNFα antagonists--what are we missing?

Revista portuguesa de pneumologia. 2014;20(1):53-4

Navarra SV, Tang B, Lu L, Lin HY, Mok CC, Asavatanabodee P, Suwannalai P, Hussein H, Rahman MU

Risk of tuberculosis with anti-tumor necrosis factor-α therapy: substantially higher number of patients at risk in Asia.

International journal of rheumatic diseases. 2014;17(3):291-8

Lee SK, Kim SY, Kim EY, Jung JY, Park MS, Kim YS, Kim SK, Chang J, Kang YA

Mycobacterial infections in patients treated with tumor necrosis factor antagonists in South Korea.

Lung. 2013;191(5):565-71

Jauregui-Amezaga A, Turon F, Ordás I, Gallego M, Feu F, Ricart E, Panés J

Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening.

Journal of Crohn's & colitis. 2013;7(3):208-12

Winthrop KL, Baxter R, Liu L, Varley CD, Curtis JR, Baddley JW, McFarland B, Austin D, Radcliffe L, Suhler E, Choi D, Rosenbaum JT, Herrinton LJ

Mycobacterial diseases and antitumour necrosis factor therapy in USA.

Annals of the rheumatic diseases. 2013;72(1):37-42

Ferrara G, Murray M, Winthrop K, Centis R, Sotgiu G, Migliori GB, Maeurer M, Zumla A

Risk factors associated with pulmonary tuberculosis: smoking, diabetes and anti-TNFα drugs.

Current opinion in pulmonary medicine. 2012;18(3):233-40

Keyser FD

Choice of Biologic Therapy for Patients with Rheumatoid Arthritis: The Infection Perspective.

Current rheumatology reviews. 2011;7(1):77-87

Mariette X, Gottenberg JE, Ravaud P, Combe B

Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries.

Rheumatology (Oxford, England). 2011;50(1):222-9

Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A, B S R B R Control Centre Consortium, Symmons DP, BSR Biologics Register

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).

Annals of the rheumatic diseases. 2010;69(3):522-8

Lalvani A, Millington KA

Screening for tuberculosis infection prior to initiation of anti-TNF therapy.

Autoimmunity reviews. 2008;8(2):147-52

Patkar NM, Teng GG, Curtis JR, Saag KG

Association of infections and tuberculosis with antitumor necrosis factor alpha therapy.

Current opinion in rheumatology. 2008;20(3):320-6

Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO

Granulomatous infectious diseases associated with tumor necrosis factor antagonists.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2004;38(9):1261-5

Long R, Gardam M

Tumour necrosis factor-alpha inhibitors and the reactivation of latent tuberculosis infection.

CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2003;168(9):1153-6